Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
EUROPEAN JOURNAL OF CANCER, cilt.50, sa.6, ss.1090-1099, 2014 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 6
- Basım Tarihi: 2014
- Doi Numarası: 10.1016/j.ejca.2014.01.006
- Dergi Adı: EUROPEAN JOURNAL OF CANCER
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1090-1099
- Hacettepe Üniversitesi Adresli: Evet
Özet
Background: Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before its commercial availability. Preliminary results of the European CUP/EAP, focusing on the elderly population (aged >= 70 years), are reported.